Solid dose formulation lends itself to the formation of very stable therapeutic or vaccine material and Glide’s vaccine candidates combine ease of administration through use of the Glide SDI®, with antigen stability that may lead to the reduction or even abolition of cold chains during distribution. The reusable spring-powered SDI® actuator delivers the vaccine subcutaneously as a solid dose, in a fraction of a second. The formulation dissolves within minutes, releasing the vaccine into the surrounding tissue. In conventional vaccine procedures there is increasing concern about needle-stick injuries to carers administering the vaccination. With the SDI®, however, there is no needle and consequently there is no danger of needle-stick injury after use. Glide has exemplified the potential value of solid dose formulation and use of the SDI® in vaccination by completing successful protection studies in seasonal influenza, diphtheria and Haemophilus influenzae. Potential dose-sparing was noted in the influenza and diphtheria studies, with potentially protective antibody responses observed after single doses of vaccine delivered by SDI®. Novel cancer and ‘Universal’ influenza peptide vaccines reliant on the production of cell mediated immunity have also been successfully formulated. Glide’s current pipeline of vaccine candidates includes an anthrax vaccine (in collaboration with Pfenex, Inc. and supported by NIAID ) and an influenza vaccine in collaboration with Cilian AG.
|Vaccine||Protective antibody||Challenge protection|
*Evidence of dose sparing
|Vaccine||Cell Mediated Immunity achieved|
|Peptide cancer vaccine|